Sinopharm Group Co. reported a nearly 10% decline in interim net profit for the first half of 2024, totaling 3.7 billion yuan, with revenue decreasing slightly by 2.07% to 294.73 billion yuan. The drop in performance was attributed to weaker sales in the retail pharmacy and medical device distribution sectors, despite a slight increase in pharmaceutical distribution revenue. Meanwhile, Sino Land Co. also experienced a significant downturn, with a 24.7% decrease in net profit to HK$4.4 billion and a 25.5% drop in property sales revenue, attributed to high interest rates and inflation. The company launched new residential projects but acknowledged ongoing economic challenges. Both companies emphasized the need for adaptability and prudent management in the face of current market conditions.